Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.
- Conditions
- Alzheimer Disease
- Interventions
- Drug: LY450139Drug: placebo
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2008-10-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 27
- Registration Number
- NCT00765115
- Locations
- 🇺🇸
For additional information regarding investigtive sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, St. Louis, Missouri, United States
Antidepressant Drug Exposure and Risk of Suicide Attempt Resulting in Medical Intervention in US Adults
- Conditions
- SuicideDepression
- First Posted Date
- 2008-10-01
- Last Posted Date
- 2010-03-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 254432
- Registration Number
- NCT00763724
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 939
- Registration Number
- NCT00762034
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: LY450139Drug: Placebo
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1111
- Registration Number
- NCT00762411
- Locations
- 🇺🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odesa, Ukraine
Back Pain in Patients With Severe Osteoporosis
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2011-06-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 650
- Registration Number
- NCT00761332
- Locations
- 🇹🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangkok, Thailand
Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD)
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2011-09-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 112
- Registration Number
- NCT00760747
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Northampton, United Kingdom
Duloxetine for Multiple Sclerosis Pain
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: PlaceboDrug: Duloxetine Hydrochloride (HCI)
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2011-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 239
- Registration Number
- NCT00755807
- Locations
- 🇵🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wroclaw, Poland
Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT00749216
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokushima, Japan
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 25
- Registration Number
- NCT00744991
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States
A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2014-12-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 41
- Registration Number
- NCT00735696
- Locations
- 🇬🇧
ImClone Investigational Site, London, United Kingdom